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Advances in cancer genome sequencing technologies have led to the identification of non–small-cell lung cancer 
(NSCLC) subtypes having distinct potentially actionable 
molecular drivers, including mutations in the kinase domain 
of human epidermal growth factor receptor-2 (HER2), which 
have been reported in approximately 4% of NSCLC cases.1 
Preclinical and clinical studies demonstrated that HER2 muta-
tions in NSCLC are associated with a favorable response to 
HER2 targeted therapies.2,3
CASE STUDY
We report a case study of a 53-year-old woman with 
lung adenocarcinoma and an HER2 exon 20 mutation (inser-
tion 774–775 AYVM) metastatic to the brain and right lung, 
who was treated with the HER2 tyrosine kinase inhibitor 
lapatinib, anti-HER2 monoclonal antibody trastuzumab, 
and antivascular endothelial growth factor antibody bevaci-
zumab. The patient was previously treated with two lines of 
systemic chemotherapy (cisplatin with docetaxel; carboplatin 
with pemetrexed) with stable disease as the best response and 
CyberKnife stereotactic radiotherapy to the brain.
Sequenom MassARRAY analysis of the primary 
tumor performed in a Clinical Laboratory Improvement 
Amendments–certified laboratory showed a HER2 exon 20 
mutation (insertion 774–775 AYVM) with no other mutations 
in an additional 52 tested oncogenes.
In October 2011, after signing informed consent, the 
patient received therapy on a protocol approved by the M.D. 
Anderson Institutional Review Board (NCT00543504) with 
a combination of lapatinib, trastuzumab, and bevacizumab. 
Her baseline computed tomography (CT) of chest, abdo-
men, and pelvis revealed metastatic lesions in the right lung, 
and a magnetic resonance imaging (MRI) of brain showed a 
treated lesion in the ventral pons and a new small right parietal 
metastasis.
The first restaging with CT of chest, abdomen, pelvis, 
and MRI brain after 6 weeks (2 cycles) of treatment showed 
marked improvement in both brain metastases and no change 
in size in the right lung lesions per Response Evaluation 
Criteria in Solid Tumors 1.0; however, some of the lung 
lesions demonstrated cavitation (Fig. 1). The patient con-
tinues to be on therapy for more than 7 months, and CT of 
chest, abdomen, pelvis and MRI of the brain, demonstrate 
continuing improvement with complete cavitation in the 
right lung lesion (Fig. 1). Treatment-related side effects were 
manageable.
DISCUSSION
It is plausible that the salutary effect observed in our 
patient was enhanced by dual HER2 inhibition. Emerging 
evidence suggests that dual targeting of epidermal growth 
factor receptor (EGFR) with an antibody and tyrosine kinase 
inhibitor may be effective in cancers, at least partially driven 
by EGFR, and can target both kinase-dependent and kinase-
independent functions.4,5 In addition, lapatinib and trastu-
zumab were combined with bevacizumab, which has known 
activity in NSCLC and could have contributed further to the 
therapeutic response.
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In conclusion, we observed that a heavily pretreated 
patient with advanced NSCLC, harboring a HER2 exon 20 
mutation, attained impressive and durable antitumor activ-
ity to dual HER2 inhibition in combination with beva-
cizumab. This supports previous anecdotal reports and 
suggests that using HER2-inhibiting strategies warrants 
further investigation in patients with NSCLC and HER2  
mutations.
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FIGURE 1.  Computed tomography of the right lung lesion at baseline, 6 weeks, and after 27 weeks of treatment. 
